UB-221

N/A

Report date: 2026/05/07 20:00:36

Base Information

Drug NameUB-221
Drug Alias NameUB-221Ascendant-221
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized
Mechanisms of ActionImmunomodulatorsImmunoglobulin epsilon Fc receptor antagonistsImmunoglobulin E inhibitors
TargetsImmunoglobulin EImmunoglobulin epsilon Fc receptor
Therapy Area/IndicationsChronic Urticaria
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryTaiwanMainland China
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesChinese Academy Of Sciences
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesUbp Greater China (Shanghai) Co LtdLiansheng Pharmaceutical (Yangzhou) Biopharmaceutical Co LtdCue Biopharma Inc +[5] 
Inactive CompaniesN/A
Active IndicationsChronic Urticaria
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A